Webinars.
Educational insights about GARD®
When you watch our webinars, you will learn in what ways GARD can support your testing needs. We cover essential topics that range from genomics and machine learning and why GARD has such robust prediction for in vitro sensitization testing, to difficult-to-test samples and quantitative potency assessment.
© SenzaGen
Interested in more information?
Contact us to discuss how the GARD assays can support your testing needs.
Oct 18, 2023
Latest GARD® innovation and research in in vitro skin and respiratory sensitization
In this webinar, you’ll explore the latest GARD® data on skin and respiratory sensitization. Emily Reinke from Inotiv-RTP will present a project in collaboration with NIH and Burleson Research Technologies. We’ll also showcase recent projects with industry partners: Merck | Johnson Matthey | ExxonMobil Biomedical Sciences | International Flavors & Fragrances (IFF) | Duearity | Inotiv-RTP
May 24, 2023
Using in vitro data in your CE marking submission of Medical Devices
In this webinar you will learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745, the MDR. *
Apr 26, 2023
Recap Webinar on SenzaGen’s 2023 SOT Exhibitor Hosted Session
Together with guest speakers Allison Greminger, PhD, DABT, of Exxon Mobil Biomedical Sciences, Inc. and Gretchen Ritacco of Research Institute for Fragrance Materials, Inc. (RIFM), SenzaGen’s Andy Forreryd, PhD. will present new GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers, and the potential to further broaden the GARD® applicability.
Feb 22, 2023
Overcoming challenges in skin sensitization testing with GARDskin OECD TG 442E
Together with guest speakers Dr Marco Corvaro, Technical Team Leader, Regulatory Toxicology at Corteva Agriscience and Gretchen Ritacco, Principal Scientist at the Research Institute for Fragrance Materials (RIFM), we discuss the challenges in skin sensitization testing and present new scientific data on agrochemical formulations, “difficult-to-test” substances, potency assessment and the potential to further broaden the applicability of the GARD assay to assess the endpoint of photosensitization.
Jan 24, 2023
Safety and Efficacy Evaluation of Cosmetic Products and Ingredients
Together with experts from CEHTRA, GenEvolutioN®, Laboratoire WatchFrog and PKDERM, we presented an overview of innovative in vitro methods and how to integrate them into the evaluation of safety and efficacy of cosmetic products and ingredients.
Oct 26, 2022
How to use in vitro assays in your biological evaluation
Our Medical Device and ISO expert Rose-Marie Jenvert, PhD will tell you more about how you can use in vitro methods for the biological evaluation of medical devices, now offered at our GLP-certified laboratories. She will also introduce our expanded medical device offering that provides guidance through the comprehensive process of biological evaluation to comply with MDR requirements.
May 25, 2022
Medical Devices’ principal mode of action by physical means: case studies on 3D reconstructed human tissues
By Dr Laura Ceriotti@VitroScreen, Dr Paolo Buratti@VitroScreen
This webinar showcase the opportunities offered by 3D reconstructed human tissues to demonstrate the physical mode of action of medical devices in line with the requirements and ethical criteria of the EU Medical Devices Regulation (MDR) 2017/745.
Key takeaways
How the principles of the 3Rs are applied in the MDR’s requirements.
How 3D reconstructed human tissues become a robust tool to define and demonstrate the principal mode of action of medical devices.
How to assess on a case by case approach the physical mode of action of medical devices according to their different therapeutic areas.
April 28, 2022
SenzaGen’s 2022 SOT Scientific Session: New GARD® data on agrochemical formulations, fragrance materials, medical devices and metals
By Dr Andy Forreryd@SenzaGen, Dr Christopher Choi@Takasago, Dr Karla Lienau@Sonova
Together with guest speakers from Takasago and Sonova, we will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. New GARD data on agrochemical formulations, fragrance materials, medical devices and metals will be presented.
Feb 17, 2022
Safer Medical Devices: In vitro assays as part of your biological evaluation
By Dr Rose-Marie Jenvert
In this webinar, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices, now offered at our GLP certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR.
Jan 20, 2022
Why choose GARD for skin sensitization testing?
By Dr Andy Forreryd
In this webinar you will get:
An introduction to GARD: How the genomic and machine learning-based technology works and its applications
Case studies: “Difficult-to-test” samples such as complex mixtures, pre/pro- haptens and substances with low water solubility
Case studies: In vitro skin sensitization assessment of medical devices using both saline and oil as extraction vehicles
Case studies: In vitro quantitative potency assessment as an alternative to LLNA
April 14, 2021
SenzaGen’s 2021 SOT poster presentations
By Dr Henrik Johansson and Dr Ron Brown
- Poster #1. Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response | Download a copy
- Poster #2. Applicability Domain of the GARD™skin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices (MDCPSS Best Overall Abstract) | Download a copy
June 17, 2020
Web-based launch: The NEW GARDskin Dose-Response
By Andy Forreryd, PhD, SenzaGen AB
May 26, 2020
Genomics and Machine Learning for In Vitro Sensitization Testing of Challenging Chemicals
By Henrik Johansson, PhD, and Andy Forreryd, PhD, SenzaGen AB
March 26, 2020
Web-based conference on “Difficult-to-test” substances and regulatory testing
By Andy Forreryd, SenzaGen AB and guest speakers from Eurofins, Lubrizol and MB Research Labs
Session recordings
Dr Andy Forreryd, SenzaGen
Helge Gehrke, Eurofins BioPharma Product Testing
Dr. George DeGeorge, MB Research Labs
February, 2020
In vitro sensitization testing based on genomics and machine learning
By Angelica Johansson, SenzaGen AB
October, 2019
In vitro sensitization testing of Medical Devices – GARDskin Medical Device
By Rose-Marie Jenvert, PhD, SenzaGen
September 2019
How are the in vitro GARD™ assays used in real life? – Cases and applications for testing of skin and respiratory sensitizers
By Andy Forreryd, PhD, SenzaGen